Pfizer Quality Improvement Request for Proposals Competitive Grant Program – Implementing Shared Decision Making in Hemophilia Patient Care
Pfizer Inc. funds research projects to integrate shared decision making and patient-reported outcomes into hemophilia care, promoting patient engagement and addressing disparities.
Funder: Pfizer Inc.
Due Dates: September 24, 2026: Extended Submission Deadline
Funding Amounts: Up to $30,000 per project (up to 2 awards); max project length 18 months; total available budget $60,000.
Summary: Supports quality improvement projects integrating shared decision making and patient-reported outcomes into hemophilia care to enhance patient engagement and address disparities.
Description
This competitive grant program, supported by Pfizer Inc., funds quality improvement (QI) projects that embed shared decision making (SDM) and patient-reported outcomes (PROs) into hemophilia care in the United States. The aim is to empower people living with hemophilia, their caregivers, and multidisciplinary care teams through collaborative treatment planning, improved communication, and individualized disease management. Projects should focus on integrating SDM tools and care algorithms, addressing healthcare disparities (geographic, gender, racial), and leveraging innovative strategies—such as digital tools and structured assessments—to capture and utilize the patient voice. System-based changes and multidisciplinary collaborations are encouraged, especially those that can demonstrate sustainable impact within healthcare settings.
